RGD DISEASE ONTOLOGY - ANNOTATIONS
RGD uses the Human Disease Ontology (DO, https://disease-ontology.org/) for disease curation across species. RGD automatically downloads each new release of the ontology on a monthly basis. Some additional terms which are required for RGD's curation purposes but are not currently covered in the official version of DO have been added. As corresponding terms are added to DO, these custom terms are retired and the DO terms substituted in existing annotations and subsequently used for curation.
Term: heroin dependence
Accession: DOID:9976
browse the term
Definition: An opiate dependence that involves the continued use of heroin despite problems related to use of the substance. (DO)
Synonyms: exact_synonym: heroin abuse; heroin addiction
primary_id: MESH:D006556
xref: EFO:0004240 ; NCI:C34694
G
Abat
4-aminobutyrate aminotransferase
IMP
RGD
PMID:10900239
RGD:10046064
NCBI chr10:7,503,351...7,599,474
Ensembl chr10:6,999,819...7,092,835
G
Abcb1a
ATP binding cassette subfamily B member 1A
treatment
ISO
associated with methadone treatment;DNA:SNP:intron (rs1128503) (human)
RGD
PMID:29173032
RGD:401976557
NCBI chr 4:26,312,403...26,488,456
Ensembl chr 4:25,158,362...25,442,709
G
Ache
acetylcholinesterase
ISO
protein:increased activity:blood
RGD
PMID:31129131
RGD:405855848
NCBI chr12:25,042,882...25,050,608
Ensembl chr12:19,407,360...19,413,651
G
Adipoq
adiponectin, C1Q and collagen domain containing
ISO
CTD Direct Evidence: marker/mechanism
CTD
PMID:15717844
NCBI chr11:91,226,524...91,240,244
Ensembl chr11:77,721,912...77,735,564
G
Adra1a
adrenoceptor alpha 1A
susceptibility
ISO
DNA:SNP:exon 4: p.R347C (rs1048101) (human)
RGD
PMID:33577997
RGD:401940110
NCBI chr15:45,005,648...45,111,416
Ensembl chr15:40,832,534...40,927,500
G
Akt1
AKT serine/threonine kinase 1
ameliorates
IMP
RGD
PMID:33619816
RGD:408346756
NCBI chr 6:137,534,810...137,555,131
Ensembl chr 6:131,713,720...131,733,921
G
Aldh2
aldehyde dehydrogenase 2 family member
susceptibility
ISO
DNA:polymorphism: :
RGD
PMID:21723677
RGD:401959204
NCBI chr12:40,610,244...40,643,220
Ensembl chr12:34,901,219...34,982,521
G
Ankk1
ankyrin repeat and kinase domain containing 1
onset susceptibility
ISO
DNA:SNPS:exon:rs17115439, rs7118900, rs1800497 (human) DNA:SNPs, haplotypes:intron, 3'flanking:rs11214598, rs2859545(human) DNA:SNP:exon:rs1800497(human) DNA:SNPs:5'UTR,exon:rs877138, rs4938013(human)
RGD
PMID:28854834 PMID:29550268 PMID:23840506 PMID:23303482
RGD:401959202 , RGD:401959205 , RGD:401959223 , RGD:401959304
NCBI chr 8:49,779,862...49,788,024
Ensembl chr 8:49,779,862...49,788,024
G
Ap2m1
adaptor related protein complex 2 subunit mu 1
IEP
protein:increased expression:medial prefrontal cortex (rat)
RGD
PMID:19160503
RGD:529195970
NCBI chr11:93,859,690...93,868,600
Ensembl chr11:80,328,041...80,364,140
G
Arrb2
arrestin, beta 2
treatment
ISO
DNA:polymorphism: :rs1045280(human) associated with methadone treatment;DNA:SNP:intron (rs1045280) (human)
RGD
PMID:33783060 PMID:29173032
RGD:401901593 , RGD:401976557
NCBI chr10:55,645,539...55,653,485
Ensembl chr10:55,146,818...55,154,850
G
Atp2b1
ATPase plasma membrane Ca2+ transporting 1
IEP
protein:decreased expression:medial prefrontal cortex (rat)
RGD
PMID:19160503
RGD:529195970
NCBI chr 7:35,622,267...35,731,904
Ensembl chr 7:33,735,871...33,843,295
G
Bche
butyrylcholinesterase
ISO
protein:increased activity:blood plasma (human)
RGD
PMID:30707402
RGD:401960085
NCBI chr 2:160,607,289...160,699,760
Ensembl chr 2:158,307,584...158,401,148
G
Bdnf
brain-derived neurotrophic factor
ISO
CTD Direct Evidence: marker/mechanism protein:decreased expression:serum
CTD RGD
PMID:17715210 PMID:17715210
RGD:401976440
NCBI chr 3:116,619,633...116,670,212
Ensembl chr 3:96,165,042...96,215,615
G
Chrm2
cholinergic receptor, muscarinic 2
ISO
DNA:SNP:intron:rs2350780 (human)
RGD
PMID:19500151
RGD:5509583
NCBI chr 4:65,981,136...66,116,128
Ensembl chr 4:65,014,144...65,149,103
G
Cnr1
cannabinoid receptor 1
treatment
ISO
DNA:SNP: :rs806368
RGD
PMID:32481444
RGD:597805904
NCBI chr 5:53,204,867...53,230,396
Ensembl chr 5:48,408,574...48,435,099
G
Comt
catechol-O-methyltransferase
susceptibility onset severity
ISO
DNA:SNP:exon 5: (rs769224) (human) DNA:SNP:exon 4: (rs4680) p.V158M (human) DNA:SNP:exon 1: (rs737866) (Human) DNA:SNP:-287A>G (human) DNA:SNP:: (rs737866) (Human) DNA:SNP:cd: p.V158M (human)
RGD
PMID:33577997 PMID:20728009 PMID:21857968 PMID:12476424 PMID:23155402 PMID:33544778 More...
RGD:401940110 , RGD:401940113 , RGD:401940140 , RGD:401940154 , RGD:401959234 , RGD:401959602
NCBI chr11:96,072,371...96,091,956
Ensembl chr11:82,568,025...82,587,642
G
Creb1
cAMP responsive element binding protein 1
treatment
IDA ISO
DNA:SNP:exon:rs35349697
RGD
PMID:21362452 PMID:23062870 PMID:24704376
RGD:401901181 , RGD:401901182 , RGD:401938627
NCBI chr 9:73,397,333...73,466,339
Ensembl chr 9:65,903,547...65,970,816
G
Ctnnb1
catenin beta 1
IEP
protein:decreased expression:medial prefrontal cortex (rat)
RGD
PMID:19160503
RGD:529195970
NCBI chr 8:129,517,576...129,544,661
Ensembl chr 8:120,639,995...120,667,111
G
Cyp2b3
cytochrome P450, family 2, subfamily b, polypeptide 3
treatment
ISO
DNA:polymorphisms: :785A>G (rs2279343), 516G>T (rs3745274)(human) DNA:SNP: :rs16974799
RGD
PMID:21790905 PMID:32481444
RGD:11097675 , RGD:597805904
NCBI chr 1:90,780,468...90,859,852
Ensembl chr 1:81,652,787...81,732,143
G
Cyp2c6
cytochrome P450, family 2, subfamily C, polypeptide 6
treatment
ISO
DNA:SNP:exon:CYP2C19*2 (681G>A,rs4244285)(human) DNA:SNPs::CYP2C19*2, CYP2C19*3(human)
RGD
PMID:24016178 PMID:24956251
RGD:401960868 , RGD:401960881
NCBI chr 1:247,879,058...247,916,804
Ensembl chr 1:237,693,094...238,057,596
G
Drd1
dopamine receptor D1
IEP
RGD
PMID:28598964
RGD:13506959
NCBI chr17:10,545,488...10,550,029
Ensembl chr17:10,540,558...10,545,002
G
Drd2
dopamine receptor D2
onset susceptibility
ISO IEP
CTD Direct Evidence: marker/mechanism DNA:SNPS:exon, intron:multiples(human) DNA:SNP:intron:rs1079597(human)
CTD RGD
PMID:11751029 PMID:28598964 PMID:28854834 PMID:23840506
RGD:13506959 , RGD:401959202 , RGD:401959223
NCBI chr 8:58,605,403...58,669,339
Ensembl chr 8:49,708,927...49,772,875
G
Drd3
dopamine receptor D3
IEP
RGD
PMID:28598964
RGD:13506959
NCBI chr11:70,385,586...70,437,793
Ensembl chr11:56,879,689...56,940,596
G
Drd4
dopamine receptor D4
susceptibility onset
ISO
DNA:SNPs:5promoter:rs1800955,rs936462(human) DNA:polymorphism:promoter:-521G>A(human) DNA:SNP,methylation::rs3758653(human)
RGD
PMID:23840506 PMID:18991844 PMID:34864042
RGD:401959223 , RGD:401959594 , RGD:401959595
NCBI chr 1:205,825,937...205,829,124
Ensembl chr 1:196,396,366...196,399,553
G
Fas
Fas cell surface death receptor
IEP
protein:increased expression:cerebral cortex (rat)
RGD
PMID:14530904
RGD:8686423
NCBI chr 1:241,212,155...241,245,774
Ensembl chr 1:231,798,960...231,832,591
G
Fkbp5
FKBP prolyl isomerase 5
susceptibility
ISO
DNA:SNPs:intron,3'utr: (rs1360780,rs3800373) (human)
RGD
PMID:24845178
RGD:401976498
NCBI chr20:6,458,931...6,577,227
Ensembl chr20:6,457,216...6,541,674
G
Fosb
FosB proto-oncogene, AP-1 transcription factor subunit
ameliorates treatment
IDA IEP
RGD
PMID:21362452 PMID:23062870 PMID:17165513
RGD:401901181 , RGD:401901182 , RGD:407571685
NCBI chr 1:88,082,324...88,089,506
Ensembl chr 1:78,954,115...78,961,465
G
Gabbr1
gamma-aminobutyric acid type B receptor subunit 1
susceptibility
ISO
DNA:SNP:intron: C>G (rs29220) (human)
RGD
PMID:26727527
RGD:11552767
NCBI chr20:1,464,534...1,494,114
Ensembl chr20:1,464,534...1,493,994
G
Gabra2
gamma-aminobutyric acid type A receptor subunit alpha 2
ISO
CTD Direct Evidence: marker/mechanism
CTD
PMID:19833324
NCBI chr14:37,451,218...37,587,458
Ensembl chr14:37,097,279...37,228,944
G
Gabrb3
gamma-aminobutyric acid type A receptor subunit beta 3
susceptibility
ISO
DNA:SNP:promoter:rs4906902(human) DNA:SNP::rs7165224(human)
RGD
PMID:25025424 PMID:19500151
RGD:405866341 , RGD:5509583
NCBI chr 1:117,602,772...117,838,230
Ensembl chr 1:108,296,124...108,698,961
G
Gabrg2
gamma-aminobutyric acid type A receptor subunit gamma 2
ISO
DNA:SNP:intron: (rs211014) (human)
RGD
PMID:17440936
RGD:402525444
NCBI chr10:26,876,926...26,965,523
Ensembl chr10:26,374,694...26,464,346
G
Gad1
glutamate decarboxylase 1
treatment susceptibility
ISO
DNA:SNPs, haplotype:multiple: DNA:SNPs,haplotypes:promoter,exon:rs1978340, rs3791878, rs11542313 (human) DNA:SNP,haplotype: :rs2058725(human)
RGD
PMID:31866536 PMID:22564729 PMID:19500151
RGD:401900128 , RGD:401900156 , RGD:5509583
NCBI chr 3:75,777,260...75,818,099
Ensembl chr 3:55,369,704...55,410,333
G
Gad2
glutamate decarboxylase 2
susceptibility
ISO
DNA:SNP: ::rs8190646(human)
RGD
PMID:19500151
RGD:5509583
NCBI chr17:89,671,718...89,734,246
Ensembl chr17:84,763,628...84,826,155
G
Gdnf
glial cell derived neurotrophic factor
ISO
DNA:SNP: :rs2910709
RGD
PMID:24022000
RGD:405849398
NCBI chr 2:58,621,327...58,647,242
Ensembl chr 2:56,895,010...56,917,209
G
Gria1
glutamate ionotropic receptor AMPA type subunit 1
treatment
ISO IEP
mRNA:increased expression:ventral striatum (human)
RGD
PMID:27863698 PMID:19940171
RGD:405096665 , RGD:4107717
NCBI chr10:41,710,540...42,030,105
Ensembl chr10:41,210,713...41,527,283
G
Gria2
glutamate ionotropic receptor AMPA type subunit 2
IEP
protein:decreased expression:medial prefrontal cortex (rat) protein:decreased expression:infralimbic area synaptosome (rat)
RGD
PMID:19160503 PMID:29134962
RGD:529195970 , RGD:596920311
NCBI chr 2:168,247,490...168,367,616
Ensembl chr 2:165,947,521...166,069,510
G
Gria3
glutamate ionotropic receptor AMPA type subunit 3
IEP
protein:decreased expression:medial prefrontal cortex (rat)
RGD
PMID:19160503
RGD:529195970
NCBI chr X:125,103,975...125,369,690
Ensembl chr X:120,238,534...120,504,096
G
Grin2a
glutamate ionotropic receptor NMDA type subunit 2A
susceptibility
ISO
DNA:repeats,SNPs,haplotype:introns:(GT)26, rs3219790,rs1102972,rs1650420,rs3104703 (human) DNA:repeats: :(GT)26 (human)
RGD
PMID:23940648 PMID:25366762
RGD:401938628 , RGD:401938629
NCBI chr10:6,136,458...6,560,003
Ensembl chr10:5,631,369...6,044,637
G
Grin2b
glutamate ionotropic receptor NMDA type subunit 2B
IEP
protein:decreased expression:medial prefrontal cortex (rat)
RGD
PMID:19160503
RGD:529195970
NCBI chr 4:170,297,811...170,775,420
Ensembl chr 4:168,599,546...169,042,279
G
Grm2
glutamate metabotropic receptor 2
IMP
RGD
PMID:30283001
RGD:38501063
NCBI chr 8:116,158,810...116,171,857
Ensembl chr 8:107,280,099...107,293,146
G
Grm2em1
glutamate metabotropic receptor 2; endonuclease induced mutant 1
IMP
KO compared to wild-type rats
RGD
PMID:30283001
RGD:38501063
G
Hcrt
hypocretin neuropeptide precursor
treatment
ISO
RGD
PMID:35984180
RGD:401960075
NCBI chr10:86,190,289...86,191,524
Ensembl chr10:85,689,465...85,691,210
G
Htr3a
5-hydroxytryptamine receptor 3A
ISO
DSNA:SNPs:promoter, intron, CDS:g.113974819C>T, g.113985089A>G, g.113989703A>G (rs1150226, rs897687, rs1176713) (human) DNA:SNPs, haplotype:multiple (human)
RGD
PMID:26227246 PMID:19500151
RGD:405096480 , RGD:5509583
NCBI chr 8:58,138,514...58,150,960
Ensembl chr 8:49,242,020...49,254,389
G
Kcnj6
potassium inwardly-rectifying channel, subfamily J, member 6
ISO
DNA:SNP: :rs2070995 (human)
RGD
PMID:20220551
RGD:6483055
NCBI chr11:47,531,312...47,778,348
Ensembl chr11:34,061,708...34,308,758
G
Lep
leptin
ISO
CTD Direct Evidence: marker/mechanism
CTD
PMID:15717844
NCBI chr 4:58,626,529...58,640,663
Ensembl chr 4:57,661,131...57,675,262
G
Ngf
nerve growth factor
treatment
ISO
CTD Direct Evidence: marker/mechanism DNA:SNP:intron:rs2239622 protein:decreased expression:serum
CTD RGD
PMID:17715210 PMID:21358750 PMID:17715210
RGD:401965390 , RGD:401976440
NCBI chr 2:192,589,580...192,642,971
Ensembl chr 2:189,901,058...189,954,452
G
Npy1r
neuropeptide Y receptor Y1
susceptibility
ISO
DNA:SNP, haplotype:intron: (rs4234955) (human) DNA:SNP:intron: (rs4518200) (human)
RGD
PMID:29465008 PMID:24845178
RGD:402463944 , RGD:401976498
NCBI chr16:27,804,416...27,814,070
Ensembl chr16:23,037,789...23,046,759
G
Nr3c1
nuclear receptor subfamily 3, group C, member 1
susceptibility
ISO
DNA:SNP, haplotype: :rs10482672
RGD
PMID:29465008
RGD:402463944
NCBI chr18:31,522,783...31,644,508
Ensembl chr18:31,271,681...31,393,375
G
Ntrk2
neurotrophic receptor tyrosine kinase 2
treatment
ISO
DNA:SNPs: :multiple
RGD
PMID:23651024
RGD:401938595
NCBI chr17:5,560,558...5,875,899
Ensembl chr17:5,559,043...5,869,136
G
Oprd1
opioid receptor, delta 1
onset treatment
ISO
DNA:SNP: :rs508448 (human) DNA:SNP:CDS:intron 1 (rs204047|rs797397) (human) DNA:SNP, haplotype:multiple (multiple) (human) DNA:SNP, haplotype:intron 1 (multiple) (human) associated with methadone treatment;DNA:SNP:intron (rs529520) (human) associated with stress-related disorder;DNA:SNP:coding synonymous,intron (rs2234918, rs2236857) (human)
RGD
PMID:28692418 PMID:31907389 PMID:34031368 PMID:22500942 PMID:29173032 PMID:30171993 More...
RGD:401831045 , RGD:401976443 , RGD:401976533 , RGD:401976535 , RGD:401976557 , RGD:401977579
NCBI chr 5:149,590,244...149,624,999
Ensembl chr 5:144,306,188...144,340,960
G
Oprk1
opioid receptor, kappa 1
treatment
IMP ISO
DNA:SNP: :rs3802279, rs3802281, and rs963549 (human)
RGD
PMID:24725195 PMID:31940240 PMID:24305833
RGD:9831447 , RGD:401827951 , RGD:401850592
NCBI chr 5:18,657,866...18,675,671
Ensembl chr 5:13,860,021...13,877,823
G
Oprl1
opioid related nociceptin receptor 1
treatment
ISO
DNA:SNP: :rs2229205
RGD
PMID:32481444
RGD:597805904
NCBI chr 3:189,209,495...189,225,406
Ensembl chr 3:168,834,003...168,839,920
G
Oprm1
opioid receptor, mu 1
severity no_association susceptibility
ISO
CTD Direct Evidence: marker/mechanism DNA:SNPs, haplotypes: :rs696522, rs1381376, rs3778151 (human) DNA:SNP, haplotype: :rs483481 (human) DNA:missense mutation:exon:p.N40D (118A>G) (rs 1799971) (human) DNA:SNPs, haplotypes: :multiple mRNA:splice variants:prefrontal cortex
CTD RGD
PMID:20201854 PMID:17157823 PMID:32189578 PMID:11424981 PMID:28976288 PMID:28692418 PMID:32506472 More...
RGD:401827940 , RGD:401827950 , RGD:401827953 , RGD:401831044 , RGD:401831045 , RGD:401831047
NCBI chr 1:45,565,371...45,818,722
Ensembl chr 1:43,160,057...43,413,409
G
Pdyn
prodynorphin
onset susceptibility no_association
ISO
DNA:repeat:promoter:rs35286251 (human) mRNA:decreased expression:periamygdaloid cortex DNA:SNP: :rs910080 (human) DNA:SNPs, repeat:promoter:rs2281285, rs2235749, rs35286251 (human) DNA:VNTR:promoter DNA:VNTR, SNPs:rs1022563, rs2235749, rs910080 (human)
RGD
PMID:30936032 PMID:24231353 PMID:35271823 PMID:29911117 PMID:29911117 PMID:30138645 PMID:21382455 More...
RGD:401850549 , RGD:401850554 , RGD:401850556 , RGD:401850561 , RGD:401850561 , RGD:401850562 , RGD:401850577
NCBI chr 3:137,354,161...137,366,503
Ensembl chr 3:116,900,992...116,913,334
G
Penk
proenkephalin
IMP
RGD
PMID:22683090
RGD:10003025
NCBI chr 5:21,981,381...21,987,074
Ensembl chr 5:17,183,806...17,189,129
G
Pomc
proopiomelanocortin
treatment
ISO IEP IDA
CTD Direct Evidence: marker/mechanism
CTD RGD
PMID:18201294 PMID:23771528 PMID:6316060
RGD:407431642 , RGD:407572514
NCBI chr 6:32,659,137...32,665,175
Ensembl chr 6:26,939,837...26,945,664
G
Retn
resistin
ISO
CTD Direct Evidence: marker/mechanism
CTD
PMID:15717844
NCBI chr12:6,508,653...6,511,115
Ensembl chr12:1,710,881...1,712,620
G
Slc6a3
solute carrier family 6 member 3
IEP
RGD
PMID:28598964
RGD:13506959
NCBI chr 1:31,537,990...31,578,962
Ensembl chr 1:29,709,443...29,750,413
G
Th
tyrosine hydroxylase
onset
ISO
DNA:SNP:5'utr:(rs10770140) (human)
RGD
PMID:32736537
RGD:405866368
NCBI chr 1:207,500,959...207,508,276
Ensembl chr 1:198,071,503...198,109,767
G
Tph1
tryptophan hydroxylase 1
ISO
DNA:SNP: :rs1799913
RGD
PMID:18181017
RGD:597621691
NCBI chr 1:106,293,695...106,314,628
Ensembl chr 1:97,157,409...97,178,344
G
Tph2
tryptophan hydroxylase 2
treatment
ISO
DNA:SNPs: :rs4290270, rs7963720 DNA:SNP: :rs1386493
RGD
PMID:18181017 PMID:32481444
RGD:597621691 , RGD:597805904
NCBI chr 7:52,571,909...52,676,305
Ensembl chr 7:50,685,694...50,789,424
G
Ttc12
tetratricopeptide repeat domain 12
susceptibility
ISO
DNA:SNP:5'UTR,intron:rs7130431(human)
RGD
PMID:23303482
RGD:401959304
NCBI chr 8:58,696,381...58,743,857
Ensembl chr 8:49,799,920...49,847,087
Term paths to the root one shortest all shortest one longest all longest one shortest and longest all